Derek Lowe has a post at his In the Pipeline blog looking at SGX Pharmaceuticals' foray into phase I trials with a therapeutic that emerged from X-ray crystallographic screening. "Here's a good example of why all of us in the industry tiptoe into Phase I trials, the first-in-man studies," Lowe writes.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.